Company intelligence / Profile preview
Puma Biotechnology, Inc.
Los Angeles, California, United Statespumabiotechnology.com ↗
- Ownership
- Public · PBYI
- Employees
- ~265
- Development stage
- Commercial
01
Overview
Puma Biotechnology has FDA-approved Nerlynx (neratinib) for HER2-positive breast cancer treatment. The company is also developing Alisertib for small cell lung cancer and HER2-negative, hormone receptor-positive metastatic breast cancer, with FDA orphan drug designation for small cell lung cancer received in 2023.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $466.7M
- Total revenue
- $56.5M
- Enterprise value
- $377.7M
Beyond the preview
Go deeper on Puma Biotechnology, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Puma Biotechnology, Inc..